COVID-19 Tanılı Hastalarda Medikal Tedavilerin Ekg Üzerine Etkisi

Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020;323(11):1061-1069. doi:10.1001/jama.2020.1585.

Bhatla A, Mayer MM, Adusumalli S, et al. COVID-19 and cardiac arrhythmias. Heart Rhythm. 2020;17(9):1439-1444. doi:10.1016/j.hrthm.2020.06.016.

RECOVERY Collaborative Group. Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19. The New England Journal of Medicine. 2020;383(21):2030-2040. doi:10.1056/nejmoa2022926.

Infectious Diseases Society of America. IDSA Guidelines on the Treatment and Management of Patients with COVID-19. (17/09/2026 tarihinde https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/ adresinden ulaşılmıştır).

Guo T, Fan Y, Chen M, et al. Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19). JAMA Cardiology. 2020;5(7):811-818. doi:10.1001/jamacardio.2020.1017.

Tisdale JE, Chung MK, Campbell KB, et al. Drug-Induced Arrhythmias: A Scientific Statement From the American Heart Association. Circulation. 2020;142(15):e214-e233. doi:10.1161/cir.0000000000000905.

Aromolaran AS, Srivastava U, Alí A, et al. Interleukin-6 inhibition of hERG underlies risk for acquired long QT in cardiac and systemic inflammation. PLOS ONE. 2018;13(12):e0208321. doi:10.1371/journal.pone.0208321.

Drew BJ, Ackerman MJ, Funk M, et al. Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. Circulation. 2010;121(8):1047-1060. doi:10.1161/circulationaha.109.192704.

Rautaharju PM, Surawicz B, Gettes LS, et al. AHA/ACCF/HRS recommendations for the standardization and interpretation of the electrocardiogram: part IV: the ST segment, T and U waves, and the QT interval: a scientific statement from the American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; the American College of Cardiology Foundation; and the Heart Rhythm Society. Endorsed by the International Society for Computerized Electrocardiology. Journal of the American College of Cardiology. 2009;53(11):982-991. doi:10.1016/j.jacc.2008.12.014.

Vandenberk B, Vandael E, Robyns T, et al. Which QT Correction Formulae to Use for QT Monitoring?. Journal of the American Heart Association. 2016;5(6):e003264. doi:10.1161/jaha.116.003264.

Roden DM, Harrington RA, Poppas A, et al. Considerations for Drug Interactions on QTc in Exploratory COVID-19 Treatment. Circulation. 2020;141(24):e906-e907. doi:10.1161/circulationaha.120.047521.

Mercuro NJ, Yen CF, Shim DJ, et al. Risk of QT Interval Prolongation Associated With Use of Hydroxychloroquine With or Without Concomitant Azithromycin Among Hospitalized Patients Testing Positive for Coronavirus Disease 2019 (COVID-19). JAMA Cardiology. 2020;5(9):1036-1041. doi:10.1001/jamacardio.2020.1834.

Pavri BB, Kloo J, Farzad D, et al. Behavior of the PR interval with increasing heart rate in patients with COVID-19. Heart Rhythm. 2020;17(9):1434-1438. doi:10.1016/j.hrthm.2020.06.009.

Chorin E, Wadhwani L, Magnani S, et al. QT interval prolongation and torsade de pointes in patients with COVID-19 treated with hydroxychloroquine/azithromycin. Heart Rhythm. 2020;17(9):1425-1433. doi:10.1016/j.hrthm.2020.05.014.

Saleh M, Gabriels J, Chang D, et al. Effect of Chloroquine, Hydroxychloroquine, and Azithromycin on the Corrected QT Interval in Patients With SARS-CoV-2 Infection. Circulation: Arrhythmia and Electrophysiology. 2020;13(6):e008662. doi:10.1161/circep.120.008662.

Cavalcanti AB, Zampieri FG, Rosa RG, et al. Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19. The New England Journal of Medicine. 2020;383(21):2041-2052. doi:10.1056/nejmoa2019014.

RECOVERY Collaborative Group. Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. The Lancet. 2021;397(10274):605-612. doi:10.1016/s0140-6736(21)00149-5.

Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the Treatment of Covid-19 - Final Report. The New England Journal of Medicine. 2020;383(19):1813-1826. doi:10.1056/nejmoa2007764.

Gottlieb RL, Vaca CE, Paredes R, et al. Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients. The New England Journal of Medicine. 2022;386(4):305-315. doi:10.1056/nejmoa2116846.

Touafchia A, Bagheri H, Carrié D, et al. Serious bradycardia and remdesivir for coronavirus 2019 (COVID-19): a new safety concerns. Clinical Microbiology and Infection. 2021;27(5):791.e5-791.e8. doi:10.1016/j.cmi.2021.02.013.

Hammond J, Leister-Tebbe H, Gardner A, et al. Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19. The New England Journal of Medicine. 2022;386(15):1397-1408. doi:10.1056/nejmoa2118542.

Marzolini C, Kuritzkes DR, Marra F, et al. Recommendations for the Management of Drug-Drug Interactions Between the COVID-19 Antiviral Nirmatrelvir/Ritonavir (Paxlovid) and Comedications. Clinical Pharmacology & Therapeutics. 2022;112(6):1191-1200. doi:10.1002/cpt.2646.

Abraham S, Nohria A, Neilan TG, et al. Cardiovascular Drug Interactions With Nirmatrelvir/Ritonavir in Patients With COVID-19: JACC Review Topic of the Week. Journal of the American College of Cardiology. 2022;80(20):1912-1924. doi:10.1016/j.jacc.2022.08.800.

RECOVERY Collaborative Group. Dexamethasone in Hospitalized Patients with Covid-19. The New England Journal of Medicine. 2021;384(8):693-704. doi:10.1056/nejmoa2021436.

Tisdale JE, Jaynes HA, Kingery JR, et al. Development and validation of a risk score to predict QT interval prolongation in hospitalized patients. Circulation: Cardiovascular Quality and Outcomes. 2013;6(4):479-487. doi:10.1161/circoutcomes.113.000152.